UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 51

Sortiert nach

Multiple myeloma

The Lancet (British edition), 2009-07, Vol.374 (9686), p.324-339

2009

Link zum Volltext

Verfügbarkeit prüfen

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

Cancer research (Chicago, Ill.), 2006-07, Vol.66 (13), p.6675-6682

2006

Link zum Volltext

Verfügbarkeit prüfen

GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo

Cancer research (Chicago, Ill.), 2012-10, Vol.72 (20), p.5374-5385

2012

Link zum Volltext

Verfügbarkeit prüfen

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)

Blood, 2007-02, Vol.109 (4), p.1669-1677

2007

Link zum Volltext

Verfügbarkeit prüfen

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma

Annals of hematology, 2018-05, Vol.97 (5), p.839-849

2018

Link zum Volltext

Verfügbarkeit prüfen

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

Cancer research (Chicago, Ill.), 2005-12, Vol.65 (24), p.11712-11720

2005

Link zum Volltext

Verfügbarkeit prüfen

Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling

Blood, 2009-02, Vol.113 (7), p.1513-1521

2009

Link zum Volltext

Verfügbarkeit prüfen

Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior—A case report

EJHaem, 2022-11, Vol.3 (4), p.1377-1380

2022

Link zum Volltext

Verfügbarkeit prüfen

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1

Oncotarget, 2014-11, Vol.5 (21), p.10237-10250

2014

Link zum Volltext

Verfügbarkeit prüfen

Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma

British journal of haematology, 2007-10, Vol.139 (1), p.55-63

2007

Link zum Volltext

Verfügbarkeit prüfen

Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma

British journal of haematology, 2008-05, Vol.141 (5), p.659-671

2008

Link zum Volltext

Verfügbarkeit prüfen

P-188: Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S140-S141

2021

Link zum Volltext

Verfügbarkeit prüfen

Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function

Hematological oncology, 2016-12, Vol.34 (4), p.200-207

2016

Link zum Volltext

Verfügbarkeit prüfen

Thalidomide in multiple myeloma - clinical trials and aspects of drug metabolism and toxicity

Expert opinion on drug metabolism & toxicology, 2008-07, Vol.4 (7), p.973-985

2008

Link zum Volltext

Verfügbarkeit prüfen

Fatty acid synthase is a novel therapeutic target in multiple myeloma

British journal of haematology, 2008-05, Vol.141 (5), p.659-671

2008

Link zum Volltext

Verfügbarkeit prüfen

The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure

Haematologica (Roma), 2006-11, Vol.91 (11), p.1555-1558

2006

Link zum Volltext

Verfügbarkeit prüfen

Abstract 660: Inhibition of centrosomal clustering suppresses tumor growth in vivo

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.660-660

2011

Link zum Volltext

Verfügbarkeit prüfen

Effect of CD34+ cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation

European journal of haematology, 2007-01, Vol.78 (1), p.21-28

2007

Link zum Volltext

Verfügbarkeit prüfen

Centrosomal Clustering – a Novel Therapeutic Target for Multiple Myeloma

Blood, 2009-11, Vol.114 (22), p.300-300

2009

Link zum Volltext

Verfügbarkeit prüfen

GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Growth in Vivo

Blood, 2008-11, Vol.112 (11), p.1639-1639

2008

Link zum Volltext

Verfügbarkeit prüfen

The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 in Multiple Myeloma

Blood, 2008-11, Vol.112 (11), p.2766-2766

2008

Link zum Volltext

Verfügbarkeit prüfen

Targeting PKC: A Novel Role for Beta-catenin in ER Stress and Apoptotic Signaling

Blood, 2008-11, Vol.112 (11), p.2763-2763

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(51)

Publikationsform

Sprache

Englisch
(51)
Japanisch
(10)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Blood
(26)
Cancer Research
(5)
British Journal Of Haematology
(4)
European Journal Of Cell Biology
(2)
European Journal Of Haematology
(2)
Haematologica
(2)
Annals Of Hematology
(1)
Bone
(1)
Clinical Lymphoma, Myeloma And Leukemia
(1)
Ejhaem
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Multiple myeloma

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling

Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior—A case report

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1

Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma

Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma

P-188: Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function

Thalidomide in multiple myeloma - clinical trials and aspects of drug metabolism and toxicity

Fatty acid synthase is a novel therapeutic target in multiple myeloma

The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure

Abstract 660: Inhibition of centrosomal clustering suppresses tumor growth in vivo

Effect of CD34+ cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation

Centrosomal Clustering – a Novel Therapeutic Target for Multiple Myeloma

GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Growth in Vivo

The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 in Multiple Myeloma

Targeting PKC: A Novel Role for Beta-catenin in ER Stress and Apoptotic Signaling

Suchergebnisse filtern